Close Menu

NEW YORK – AI-driven cancer detection firm Freenome said this week that it has begun a prospective clinical trial to clinically validate the multi-omic and epigenomic test it has developed for blood-based detection of colorectal cancer and pre-cancerous lesions.

The trial, called PREEMPT CRC, will enroll 14,000 asymptomatic, average-risk patients between the ages of 45 and 85 undergoing a screening colonoscopy, and is intended to support a bid for premarket approval by the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.